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Differences between the oral changes 
presented by patients with solid 
and hematologic tumors during the 
chemotherapeutic treatment
Objective: This study sought to identify the differences between the 
oral changes presented by patients with solid and hematologic tumors 
during chemotherapeutic treatment. Methodology: This is an observational, 
prospective and quantitative study using direct documentation by follow-up 
of 105 patients from 0 to 18 years using the modified Oral Assessment Guide 
(OAG). Of the 105 patients analyzed, 57 (54.3%) were boys with 7.3 years 
(±5.2) mean age. Hematologic neoplasms accounted for 51.4% of all cases. 
Results: Voice, lips, tongue, and saliva changes were not significantly different 
(p>0.05) between patients with solid or hematologic tumors and during the 
follow-up. From the 6th until the 10th week of chemotherapeutic treatment 
alterations in swallowing function, in the mucous membrane (buccal mucosa 
and palate), in the labial mucosa, and in the gingiva occurred and were 
distributed differently between the two tumors groups (p<0.05). The main 
alterations were observed in patients with hematologic tumors. Conclusion: It 
was concluded that the oral changes during the chemotherapeutic treatment 
occurred especially in swallowing function, in the mucous membrane, in the 
labial mucosa and in the gingiva, and these alterations were found mainly 
in patients with hematologic tumors.
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Introduction
Cancer is one of the most significant public health 
problems, and its global incidence has increased by 
approximately 20.0% over the last decade, with a 
projected onset of 27 million new cases in 2030.1
Pediatric cancers are rare when compared with 
those affecting adults, accounting for 1% to 3% of the 
malignant tumors worldwide. Although these tumors 
usually have brief latency periods and are aggressive 
and fast growing, they respond well to antineoplastic 
therapies, with positive prognoses and likelihoods of 
cure, provided they are diagnosed early.2-4
Chemotherapy is involved in most treatments for 
pediatric cancers,5 and acts on most types of tumors 
affecting children and adolescents via chemical agents 
that affect cell growth and division processes.6 This 
effect causes changes throughout the gastrointestinal 
tract, given the cell renewal rate of cancer. Younger 
patients are more likely to be affected by chemotherapy 
in the oral cavity.5 The main alterations include oral 
mucositis, xerostomia, dysgeusia, and difficulties in 
swallowing saliva and food.5,7
Oral mucositis is one of the most common and 
important alterations in the lips and oral cavity, and 
when associated to xerostomia these are responsible 
for extremely debilitating conditions such as the 
painful inflammatory/ulcerative reaction of the oral 
mucosa, which stands out among these alterations. 
From these changes, complications in oral functions 
also occur and patients may become unable to feed 
or communicate. Moreover, oral mucositis can spread 
throughout the gastrointestinal tract,8,9 resulting in 
severe discomfort that can prevent these individuals 
from chewing, swallowing, and speaking.10-13
Such ulcerations resulting from chemotherapy 
can cause intense pain and may require the use of 
opioid analgesics, hospitalization and complementary 
nutrition. Furthermore, oral mucositis may contribute 
to the interruption of cancer treatment, promoting 
survival reduction. The presence of these ulcers in 
immunocompromised patients may facilitate the 
entry of microorganisms into the body, increasing 
the risk of death from sepsis. This clinical condition 
thus represents a costly situation for public or private 
health systems.14
Extensive knowledge about the development of 
oral mucositis induced by chemotherapy in different 
clinical and pathological conditions is required for 
its prevention, control, and treatment. Different 
types of tumors require different therapeutic 
protocols, and this may represent a risk factor 
for the occurrence of lesions resulting from the 
direct action of chemotherapeutic agents on the 
mucosal epithelial cells or from the suppression of 
proinflammatory chemical mediators, for example of 
tumor necrosis factor (TNF-α), interleukin 1-β (IL-
1β) and interleukin-6 (IL-6) produced by neutrophils 
and macrophages in response to the microorganisms 
present in the lesion.15 The presence of these cytokines 
in the saliva of cancer patients undergoing treatment 
is also significantly associated with oral candidosis 
lesions and HSV infection.16
The tumor type is one of the factors that affect the 
occurrence, severity and duration of oral mucositis.8,17 
Therefore, a differentiated approach for pediatric 
cancer patients with hematologic and solid tumors 
is crucial, given that they may present different oral 
changes during chemotherapy. Given this context, this 
study sought to identify the major oral damage related 
to chemotherapy among pediatric cancer patients, and 




This is an observational, longitudinal, prospective, 
and quantitative study using an inductive approach, 
and a comparative-statistical procedure by a direct 
documentation technique. 
Ethical considerations
This study was approved by the Human Research 
Ethics Committee under Certificate of Presentation 
for Ethical Appreciation no. 12922113.8.0000.5188.
Patients
The patients evaluated were between 0 and 
18 years old and treated at the Hospital Napoleão 
Laureano located in João Pessoa, Paraíba, Brazil. 
This hospital is recognized as a reference center for 
the prevention, diagnosis, and treatment of cancer 
in the state of Paraíba, performing approximately 
7,000 monthly patient visits, including consultations, 
examinations and surgeries, and providing treatment 
to 3,300 patients per month on average.
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Inclusion criteria – Patients between 0 and 19 years 
old with a primary diagnosis of malignant neoplasm 
treated at the Hospital by the Brazilian Unified Health 
System (SUS) with chemotherapy as the exclusive 
treatment over the first months were considered 
as eligible for the current study. In oncology, the 
ages between 0 to 19 years old are considered as 
the pediatric age group since the tumors in children 
and adolescents within this age range behave in a 
similar way regarding the development and response 
to treatment; thus, being treated by pediatric 
oncologists.2 For this reason, the inclusion criteria of 
this study established the minimum age for inclusion 
of 0 years old and maximum of 19 years old.
Exclusion criteria – Patients with oral mucosa 
inflammation at diagnosis, initiation of radiotherapy 
or surgical treatment concomitant with chemotherapy 
before completing the evaluation period of the 
study were excluded from this study. Furthermore, 
patients with re-initiation of treatment for recurrent 
neoplasm, impaired health status, and interruption 
(for any reason) of the follow-up of this study were 
also excluded.
Sample
The hospital census sample was recruited between 
April 2013 and July 2015, for 105 patients in total.
Data collection
Data collection was performed at the dental office 
of the Pediatrics Department and at the bedsides of 
inpatients. The evaluations were performed by a single 
and previously calibrated examiner (kappa=0.87), 
using artificial lighting to improve the visualization of 
the oral cavity.
The modified Oral Assessment Guide (OAG; Figure 
1) was used for data collection. This guide evaluates 
the oral functions and structures according the degree 
of commitment, and is recognized by the scientific 
community for the evaluation of changes in the oral 
mucosa resulting from antineoplastic treatment using 
chemotherapeutic agents. This instrument evaluates 
8 items according to the oral health impairment scale, 
scoring each item from 1 to 3, being: 1=normal 
conditions; 2=mild-to-moderate changes in epithelial 
integrity or function; and 3=severe impairment, with 
severe alterations to epithelial integrity or function.17-20
The oral health conditions were monitored for 
10 weeks from the start of chemotherapy because 
this period is critical for the onset of oral alterations 
resulting from chemotherapy.19 The chemotherapeutic 
agent classes that were administered to patients in 
each week of treatment were also collected.
Data analysis
Descriptive and inferential statistics (association 
tests such as the Chi-square test with Yates’s 
continuity correction) were applied to analyze the data 
using IBM SPSS 21.0 at 5% significance level.
Results
The mean age of the patients was 7.3 (±5.2) years, 
with a median of 7.3 years (range=0-18 years), with 
a higher concentration of malignant neoplasms at the 
Item Score
1 2 3
Voice Normal Deeper or raspy Difficult talking or painful speech
Swallowing Normal swallowing Some pain upon swallowing Unable to swallow
Lips Smooth and moist Dry or cracked Ulcerated bleeding
Tongue Pink and moist and papillae 
present
Coated or loss of papillae with a 
shiny appearance with or without 
redness
Blistered or cracked
Saliva Watery Thick or ropy Absent
Mucous membrane 
(buccal mucosa, palate)
Pink and moist Reddened or coated (increased 
whiteness) without ulceration
Ulceration with or without 
bleeding
Mucous membrane (labial 
mucosa)
Pink and moist Reddened or coated (increased 
whiteness) without ulceration
Ulceration with or without 
bleeding
Gingiva Pink and stippled and firm Oedematous with or without 
redness
Spontaneous bleeding or 
bleeding with pressure
1= No alteration of normality; 2= Moderate alterations; 3= Severe alterations
Figure 1- Modified Oral Assessment Guide to monitor the oral health of patients undergoing chemotherapy
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ages of 2 (n=18; 17.0%), 3 (n=10; 9.5%), and 4 
years (n=16; 15.2%), as well as among boys (n=57; 
54.3%). 
Of the patients evaluated, 48.6% (n=51) were 
diagnosed with solid tumors primarily located in the 
left kidney (Wilms’s tumor; n=13; 25.5%), followed by 
the right femur (osteosarcoma; n=9; 17.6%). Of the 
patients with hematologic tumors, the most prevalent 
underlying disease was acute lymphoblastic leukemia 
(n=42; 77.7%).
Tables 1, 2, and 3 present the distribution of 
pediatric cancer patients according to the degree 
of changes in the structures/functions of the 
stomatognathic system over the 10-week evaluation 
None Moderate Severe Total
1
Voice 1 49 (96.1%) 2 (3.9%) - 51 (100.0%)
1.000
2 51 (94.4%) 3 (5.6%) - 54 (100.0%)
Swallowing 1 47 (92.2%) 4 (7.8%) 0 (0.0%) 51 (100.0%)
0.428
2 51 (94.4%) 2 (3.7%) 1 (1.9%) 54 (100.0%)
Lips 1 33 (64.7%) 13 (25.5%) 5 (9.8%) 51 (100.0%)
0.743
2 35 (64.8%) 16 (29.6%) 3 (5.6%) 54 (100.0%)
Tongue 1 47 (92.2%) 0 (0.0%) 4 (7.8%) 51(100.0%)
0.428
2 51 (94.4%) 1 (1.9%) 2 (3.7%) 54 (100.0%)
Saliva 1 14 (27.5%) 31 (60.8%) 6(11.8%) 51 (100.0%)
0.764
2 16 (29.6%) 34 (63.0%) 4 (7.4%) 54 (100.0%)
Mucous membrane (buccal mucosa, palate) 1 48 (94.1%) 2 (3.9%) 1 (2.0%) 51 (100.0%)
0.111
2 54 (100.0%) 0 (0.0%) 0 (0.0%) 54 (100.0%)
Labial mucosa 1 49 (96.1%) 2 (3.9%) - 51 (100.0%)
0.234
2 54 (100.0%) 0 (0.0%) - 54 (100.0%)
Gingiva 1 50 (98.0%) 0 (0.0%) 1 (2.0%) 51 (100.0%)
0.243
2 50 (92.6%) 3 (5.6%) 1 (1.9%) 54 (100.0%)
2
Voice 1 49 (96.1%) 2 (3.9%) - 51 (100.0%)
1.000
2 51 (94.4%) 3 (5.6%) - 54 (100.0%)
Swallowing 1 50 (98.0%) 1 (2.0%) - 51 (100.0%)
1.000
2 53 (98.1%) 1 (1.9%) - 54 (100.0%)
Lips 1 32 (62.7%) 10 (19.6%) 9 (17.6%) 51 (100.0%)
0.098
2 26 (48.1%) 21 (38.9%) 7 (13.0%) 54 (100.0%)
Tongue 1 50 (98.0%) - 1 (2.0%) 51  (100.0%)
1.000
2 52 (96.3%) - 2 (3.7%) 54 (100.0%)
Saliva 1 12 (23.5%) 34 (66.7%) 5 (9.8%) 51 (100.0%)
0.913
2 12 (22.2%) 35 (64.8%) 7(13.0%) 54 (100.0%)
Mucous membrane (buccal mucosa, palate) 1 48 (94.1%) 3 (5.9%) 0 (0.0%) 51 (100.0%)
0.299
2 51 (94.4%) 1 (1.9%) 2 (3.7%) 54 (100.0%)
Labial mucosa 1 40 (78.4%) 7(13.7%) 4 (7.8%) 51 (100.0%)
0.536
2 40 (74.1%) 6(11.1%) 8 (14.8%) 54 (100.0%)
Gingiva 1 49 (96.1%) 1 (2.0%) 1 (2.0%) 51 (100.0%)
0.485
2 51 (94.4%) 3 (5.6%) 0 (0.0%) 54 (100.0%)
3
Voice 1 49 (96.1%) - 2 (3.9%) 51 (100.0%)
0.234
2 54 (100%) - 0 (0.0%) 54 (100.0%)
Swallowing 1 47 (92.2%) 2 (3.9%) 2 (3.9%) 51 (100.0%)
0.327
2 53 (98.1%) 1 (1.9%) 0 (0.0%) 54 (100.0%)
Lips 1 36 (70.6%) 8 (15.7%) 7 (13.7%) 51 (100.0%)
0.505
2 33 (61.1%) 9 (16.7%) 12 (22.2%) 54 (100.0%)
Tongue 1 48 (94.1%) 1 (2.0%) 2 (3.9%) 51 (100.0%)
0.803
2 52 (96.3%) 1 (1.9%) 1 (1.9%) 54 (100.0%)
Saliva 1 19 (37.3%) 27 (52.9%) 5 (9.8%) 51 (100.0%)
0.174
2 12 (22.2%) 38 (70.4%) 4 (7.4%) 54 (100.0%)
Mucous membrane (buccal mucosa, palate) 1 47 (92.2%) 2 (3.9%) 2 (3.9%) 51 (100.0%)
0.165
2 48 (88.9%) 0 (0.0%) 6 (11.1%) 54 (100.0%)
Labial mucosa 1 46 (90.2%) 2 (3.9%) 3 (5.9%) 51 (100.0%)
0.228
2 43 (79.6%) 2 (3.7%) 9 (16.7%) 54 (100.0%)
Gingiva 1 47 (92.2%) 1 (2.0%) 3 (5.9%) 51 (100.0%)
0.322
2 49 (90.7%) 4 (7.4%) 1 (1.9%) 54 (100.0%)
Table 1- Distribution of pediatric cancer patients by the structural impairment degree of the stomatognathic system in the first 4 weeks of 
evaluation following chemotherapy onset
Continued on the next page
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after starting chemotherapy. No significant differences 
(p>0.05) were found between patients with solid 
tumors and those with hematologic tumors with 
regard to the changes assessed in the OAG (i.e., 
voice, lips, tongue, and saliva) until the 5th week of 
chemotherapeutic treatment.
Conversely, from the 6th week of treatment 
onwards, the oral changes began to appear differently 
between the two groups of patients with different 
types of tumors. For the better presentation of these 
results, the differences verified will be described in 
the sequence these alterations were evaluated by the 
data collection instrument (OAG). 
Regarding swallowing function, a significant 
difference (p=0.028) in impairment was assessed 
between the patients with solid and hematologic 
tumors on the 10th week, with 3.9% of patients with 
solid tumors showing moderate impairments (e.g., 
swallowing difficulty) when compared with 9.3% of 
patients with hematologic tumors showing the more 
severe alteration (e.g., swallowing impossibility).
In mucous membrane (buccal mucosa and palate), 
significant differences (p=0.027) were observed 
between patients with solid and hematologic tumors on 
the 9th week, with no change in normality for patients 
with solid tumors when compared to those with 
hematologic tumors, with 11.1% of patients in this 
group showing moderate changes during this period.
Significant differences in the labial mucosa were 
found between patients with solid and hematologic 
tumors on the 6th (p=0.001), 8th (p=0.030), and 
10th (p<0.001) weeks. On the 6th week, moderate 
impairment affected 11.8% more solid tumors patients 
than hematologic tumors patients. Severe alterations 
for the same site affected more the hematologic 
tumors patients (18.4% more than in solid tumors 
patients). On the 8th week, the labial mucosa changes 
occurred mainly in hematologic tumors patients, 
considering the occurrence of moderate and severe 
alterations, respectively, 5.6% and 9.1% higher than 
in the solid tumors group. In the 10th week, patients 
with solid tumors showed no changes in the normality 
of the labial mucosa when compared to 14.8% with 
moderate changes, and 7.4% with severe changes in 
the hematologic tumors group. 
Significant differences in gingiva changes were 
found in patients with solid and hematologic tumors 
in the 6th week (p=0.044), with 2.0% of the patients 
with solid tumors showing severe impairment (e.g., 
spontaneous bleeding), when compared to 3.7% of 
patients with hematologic tumors showing the same 
condition, and only hematologic tumors patients 
presented moderate alterations in gingiva (9.3%). 
On the 10th week, a significant difference (p=0.040) 
was also found between the patient groups. Patients 
with solid tumors showed no changes, whereas 9.3% 
of the patients with hematologic tumors presented 
spontaneous gingiva bleeding. 
Table 4 shows the distribution of the chemotherapeutic 
agent classes that were administered to patients 
with hematologic or solid tumors in each week of 
treatment. Except in the 3rd week the antimetabolites 
agents – class that includes methotrexate and the 
5-fluorouracil –, were administered mainly to patients 
4
Voice 1 48 (94.1%) 1 (2.0%) 2 (3.9%) 51 (10.00%)
0.850
2 51 (94.4%) 2 (3.7%) 1 (1.9%) 54 (100.0%)
Swallowing 1 49 (96.1%) 1 (2.0%) 1 (2.0%) 51 (100.0%)
0.807
2 50 (92.6%) 3 (5.6%) 1 (1.9%) 54 (100.0%)
Lips 1 36 (70.6%) 7 (13.7%) 8(15.7%) 51 (100.0%)
0.955
2 36 (66.7%) 8 (14.8%) 10(18.5%) 54 (100.0%)
Tongue 1 46 (90.2%) 2 (3.9%) 3 (5.9%) 51(100.0%)
0.202
2 51 (94.4%) 3 (5.6%) 0 (0.0%) 54 (100.0%)
Saliva 1 10 (19.6%) 36 (70.6%) 5 (9.8%) 51 (100.0%)
0.095
2 16 (29.6%) 27 (50.0%) 11(20.4%) 54 (100.0%)
Mucous membrane (buccal mucosa, palate) 1 45 (88.2%) 5 (9.8%) 1 (2.0%) 51 (100.0%)
0.520
2 48 (88.9%) 3 (5.6%) 3 (5.6%) 54 (100.0%)
Labial mucosa 1 44 (86.3%) 5 (9.8%) 2 (3.9%) 51 (100.0%)
0.575
2 47 (87.0%) 3 (5.6%) 4 (7.4%) 54 (100.0%)
Gingiva 1 45 (88.2%) 3 (5.9%) 3 (5.9%) 51 (100.0%)
0.093
2 53 (98.1%) 1 (1.9%) 0 (0.0%) 54 (100.0%)
Chi-square test with Yates’s continuity correction, α=5%
1= Solid tumors; 2= Hematologic tumors. Empty spaces= no record of degree of impairment according to the OAG regarding the anatomical 
site/function for the evaluation week
Continued from previous page
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with hematologic cancer, being the frequencies of: 1st 
week (78.0%); 2nd week (80.4%); 4th week (79.6% 
when isolated and 100.0% in association to natural 
products); 5th week (79.6%); 6th week (81.2% when 
isolated and 100.0% in association to alkylating 
agents, natural and miscellaneous products); 7th week 
(81.1% when isolated and 100.0% in association 
to alkylating agents, natural and miscellaneous 
products); 8th week (82.1% when isolated and 










Voice 1 48 (94.1%) 2 (3.9%) 1 (2.0%) 51 (100.0%)
0.480
2 53 (98.1%) 0 (0.0%) 1 (1.9%) 54 (100.0%)
Swallowing 1 49 (96.1%) - 2 (3.9%) 51 (100.0%)
0.611
2 53 (98.1%) - 1 (1.9%) 54 (100.0%)
Lips 1 47 (92.2%) 4 (7.8%) 0 (0.0%) 51 (100.0%)
0.197
2 52 (96.3%) 1 (1.9%) 1 (1.9%) 54 (100.0%)
Tongue 1 47 (92.2%) 4 (7.8%) 0 (0.0%) 51(100.0%)
0.197
2 52 (96.3%) 1 (1.9%) 1(1.9%) 54 (100.0%)
Saliva 1 13 (25.5%) 33 (64.7%) 5 (9.8%) 51 (100.0%)
0.282
2 20 (37.0%) 32 (59.3%) 2 (3.7%) 54 (100.0%)
Mucous membrane (buccal mucosa, palate) 1 50 (98.0%) 0 (0.0%) 1 (2.0%) 51 (100.0%)
0.118
2 48 (88.9%) 4 (7.4%) 2 (3.7%) 54 (100.0%)
Labial mucosa 1 50 (98.0%) 0 (0.0%) 1 (2.0%) 51 (100.0%)
0.091
2 47 (87.0%) 2 (3.7%) 5 (9.3%) 54 (100.0%)
Gingiva 1 49 (96.1%) 1 (2.0%) 1 (2.0%) 51 (100.0%)
0.807
2 50 (92.6%) 3 (5.6%) 1 (1.9%) 54 (100.0%)
6
Voice 1 50 (98.0%) 0 (0.0%) 1 (2.0%) 51 (100.0%)
0.738
2 53 (98.1%) 1 (1.9%) 0 (0.0%) 54 (100.0%)
Swallowing 1 49 (96.1%) 0 (0.0%) 2 (3.9%) 51 (100.0%)
0.180
2 52 (96.3%) 2 (3.7%) 0 (0%0) 54 (100.0%)
Lips 1 38 (74.5%) 6 (11.8%) 7 (13.7%) 51 (100.0%)
0.347
2 34 (63.0%) 12 (22.2%) 8 (14.8%) 54 (100.0%)
Tongue 1 46 (90.2%) 1 (2.0%) 4 (7.8%) 51 (100.0%)
0.068
2 52 (96.3%) 2 (3.7%) 0 (0.0%) 54 (100.0%)
Saliva 1 17 (33.3%) 29 (56.9%) 5 (9.8%) 51 (100.0%)
0.602
2 16 (29.6%) 29 (53.7%) 9(16.7%) 54 (100.0%)
Mucous membrane (buccal mucosa, palate) 1 45 (88.2%) 6(11.8%) - 51 (100.0%)
0.056
2 53 (98.1%) 1 (1.9%) - 54 (100.0%)
Labial mucosa 1 43 (84.3%) 7(13.7%) 1 (2.0%) 51 (100.0%)
0.001
2 42 (77.8%) 1 (1.9%) 11 (20.4%) 54 (100.0%)
Gingiva 1 50 (98.0%) 0 (0.0%) 1 (2.0%) 51 (100.0%)
0.044
2 47 (87.0%) 5 (9.3%) 2 (3.7%) 54 (100.0%)
7
Voice 1 50 (98.0%) - 1 (2.0%) 51 (100.0%)
0.486
2 54 (100.0%) - 0 (0.0%) 54 (100.0%)
Swallowing 1 49 (96.1%) - 2 (3.9%) 51 (100.0%)
0.234
2 54 (100.0%) - 0 (0.0%) 54 (100.0%)
Lips 1 45 (88.2%) 2 (3.9%) 4 (7.8%) 51 (100.0%)
0.088
2 53 (98.1%) 0 (0.0%) 1 (1.9%) 54 (100.0%)
Tongue 1 45 (88.2%) 2 (3.9%) 4 (7.8%) 51 (100.0%)
0.088
2 53 (98.1%) 0 (0.0%) 1 (1.9%) 54 (100.0%)
Saliva 1 12 (23.5%) 34 (66.7%) 5 (9.8%) 51 (100.0%)
0.784
2 16 (29.6%) 34 (63.0%) 4 (7.4%) 54 (100.0%)
Mucous membrane (buccal mucosa, palate) 1 51(100.0%) 0 (0.0%) 0 (0.0%) 51 (100.0%)
0.496
2 51 (94.4%) 2 (3.7%) 1 (1.9%) 54 (100.0%)
Labial mucosa 1 47 (92.2%) 1 (2.0%) 3 (5.9%) 51 (100.0%)
0.852
2 50 (92.6%) 0 (0.0%) 4 (7.4%) 54 (100.0%)
Gingiva 1 49 (96.1%) 1 (2.0%) 1 (2.0%) 51 (100.0%)
0.807
2 50 (92.6%) 3 (5.6%) 1 (1.9%) 54 (100.0%)
Table 2- Distribution of pediatric cancer patients by the structural impairment degree of the stomatognathic system of the 5th to 8th weeks 
of evaluation following chemotherapy onset
Continued on the next page
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and miscellaneous products); 9th week (82.0% when 
isolated and 100.0% in association to alkylating 
agents, natural and miscellaneous products); and in 
the 10th week (81.1%). 
Discussion
Oral changes caused by oral mucositis are the 
most significant comorbidities after the start of 
chemotherapy,8-11 and based on the assumption that 
these manifestations may be different between groups 
of patients with solid and hematologic tumors, we 
conducted this study to evaluate this hypothesis, 
seeking to serve as a guide for decision making in oral 
health care for these patients.
According to previous studies, the incidence of 
oral complications resulting from chemotherapeutic 
treatments ranges from 30% to 100% in pediatric 
cancer patients,7,20-22 thus, these children are a high-
risk group for developing oral manifestations due to 
the high mitosis rates in the oral mucosa.23
This study conducted a prospective evaluation of 
patients from 0 to 18 years old who were subjected to 
chemotherapy to treat solid or hematologic malignant 
tumors for a follow-up period of 10 weeks. The 
outcome of interest was the occurrence of changes 
in the components of the stomatognathic system 
according to the modified OAG.19 The main researchers 
in pediatric oncology have used this instrument 
worldwide,23,24 and allows the weekly monitoring of 
the oral health conditions in pediatric cancer patients, 
evaluating eight sites/functions of the stomatognathic 
system and classifying them according to the degree 
of impairment, from normal conditions to moderate 
and severe alterations in functions and oral mucosa.
The results of this study did not show significant 
differences in the changes verified in the voice, lips, 
tongue, and saliva (according to the OAG) between 
patients with solid or hematologic tumors. This finding 
suggests that studies on and the oral care for these 
patients should not be different for the two groups of 
patients. In other words, concerns about the prevention 
and monitoring of oral changes should be similar for 
both groups because the patterns of impairment were 
the same for both solid and hematologic tumors over 
the initial 5-week period of chemotherapy.
However, starting from 6th week of chemotherapeutic 
treatment, significant differences were found between 
patients with solid and hematologic tumors in oral 
changes, being these alterations verified in labial 
mucosa, mucous membrane, gingiva and swallowing. 
Such difference was identified in all weeks (6th, 8th, 
9th and 10th), with moderate and severe alterations 
in labial mucosa, mucous membrane and gingiva 
being more common in the hematologic group. On 
the other hand, the alterations in swallowing were 
more significant in group of solid tumor patients in 
10th week of treatment. The existence of a greater 
impairment in patients with hematologic tumors from 
the 6th week onwards suggests that these patients 
should receive a special attention from the beginning 
of the 2nd month of antineoplastic treatment, focusing 
on approaches that can prevent serious impairments, 
Chi-square test with Yates’s continuity correction, α=5
1= Solid tumors; 2= Hematologic tumors. Empty spaces= no record of degree of impairment according to the OAG regarding the anatomical 
site/function for the evaluation week
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Voice 1 50 (98.0%) - 1 (2.0%) 51 (100.0%)
0.486
2 54 (100.0%) - 0 (0.0%) 54 (100.0%)
Swallowing 1 46 (90.2%) 1 (2.0%) 4 (7.8%) 51 (100.0%)
0.071
2 50 (92.6%) 4 (7.4%) 0 (0.0%) 54 (100.0%)
Lips 1 47 (92.2%) 2 (3.9%) 2 (3.9%) 51 (100.0%)
0.377
2 50 (92.6%) 4 (7.4%) 0 (0.0%) 54 (100.0%)
Tongue 1 47 (92.2%) 2 (3.9%) 2 (3.9%) 51 (100.0%)
0.377
2 50 (92.6%) 4 (7.4%) 0 (0.0%) 54 (100.0%)
Saliva 1 49 (96.1%) 0 (0.0%) 2 (3.9%) 51 (100.0%)
0.059
2 50 (92.6%) 4 (7.4%) 0 (0.0%) 54 (100.0%)
Mucous membrane (buccal mucosa, palate) 1 49 (96.1%) 0 (0.0%) 2 (3.9%) 51 (100.0%)
0.059
2 50 (92.6%) 4 (7.4%) 0 (0.0%) 54 (100.0%)
Labial mucosa 1 50 (98.0%) 0 (0.0%) 1 (2.0%) 51 (100.0%)
0.030
2 45 (83.3%) 3 (5.6%) 6 (11.1%) 54 (100.0%)
Gingiva 1 50 (98.0%) 1 (2.0%) 0 (0.0%) 51 (100.0%)
0.427
2 49 (90.7%) 2 (3.7%) 3 (5.6%) 54 (100.0%)
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especially in the labial mucosa. The concern with 
these patients becomes even greater because their 
hematologic malignancies compromise the immune 
system, disrupting its homeostasis.25,26 Therefore, this 
group of patients may already start chemotherapy 
with a level of immunosuppression, and this condition 
is one of the main systemic effects recorded during 
chemotherapy.25 Thus, since patients with hematologic 
cancers show more serious degrees of impairment than 
those with solid tumors in the labial mucosa, the risk 
of systemic compromise through the ulcerated labial 
mucosa is even more worrying, and we expect that 
the results of this study can be used to change some 
care practices in the oral health of patients, possibly 
including oral health services in the multiprofessional 
team that assists children and adolescents in cancer 
therapy. 
In the 10th week of evaluation, an additional 
concern arose because of the greater changes in 
swallowing among patients with solid disease. This 
oral ability is crucial for children and adolescents to 
reach the nutritional indices that support antineoplastic 
therapies.27 Although worse swallowing impairments 
have been assessed among patients with solid tumors, 
moderate degrees of impairment might progress 
to greater functional impairments in patients with 
hematologic tumors, and according to our results, 
moderate alterations were more frequently found 
in patients with hematologic tumors; therefore, the 
oral care should be equally focused in both groups of 
neoplasms.
The differences found between the patient 
Table 3- Distribution of pediatric cancer patients by the structural impairment degree of the stomatognathic system in the 9th and 10th 










Voice 1 50 (98.0%) - 1 (2.0%) 51 (100.0%)
0.486
2 54 (100.0%) - 0 (0.0%) 54 (100.0%)
Swallowing 1 49 (96.1%) 0 (0.0%) 2 (3.9%) 51 (100.0%)
0.059
2 50 (92.6%) 4 (7.4%) 0 (0.0%) 54 (100.0%)
Lips 1 46 (90.2%) 5 (9.8%) 0 (0.0%) 51 (100.0%)
1.000
2 48 (88.9%) 5 (9.3%) 1 (1.9%) 54 (100.0%)
Tongue 1 46 (90.2%) 5 (9.8%) 0 (0.0%) 51 (100.0%)
1.000
2 48 (88.9%) 5 (9.3%) 1 (1.9%) 54 (100.0%)
Saliva 1 12 (23.5%) 34 (66.7%) 5 (9.8%) 51 (100.0%)
0.543
2 10 (18.5%) 41 (75.9%) 3 (5.6%) 54 (100.0%)
Mucous membrane (buccal mucosa, palate) 1 51(100.0%) 0 (0.0%) - 51 (100.0%)
0.027
2 48 (88.9%) 6 (11.1%) - 54 (100.0%)
Labial mucosa 1 50 (98.0%) 0 (0.0%) 1 (2.0%) 51 (100.0%)
0.084
2 47 (87.0%) 1 (1.9%) 6 (11.1%) 54 (100.0%)
Gingiva 1 51 (100.0%) 0 (0.0%) - 51 (100.0%)
0.496
2 52 (96.3%) 2 (3.7%) - 54 (100.0%)
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Voice 1 50 (98.0%) - 1 (2.0%) 51 (100.0%)
0.486
2 54 (100.0%) - 0 (0.0%) 54 (100.0%)
Swallowing 1 49 (96.1%) 0 (0.0%) 2 (3.9%) 51 (100.0%)
0.028
2 49 (90.7%) 5 (9.3%) 0 (0.0%) 54 (100.0%)
Lips 1 51 (100.0%) 0 (0.0%) 0 (0.0%) 51 (100.0%)
0.085
2 49 (90.7%) 4 (7.4%) 1 (1.9%) 54 (100.0%)
Tongue 1 51 (100.0%) 0 (0.0%) 0 (0.0%) 51(100.0%)
0.085
2 49 (90.7%) 4 (7.4%) 1 (1.9%) 54 (100.0%)
Saliva 1 19 (37.3%) 27 (52.9%) 5 (9.8%) 51 (100.0%)
0.726
2 17 (31.5%) 33 (61.1%) 4 (7.4%) 54 (100.0%)
Mucous membrane (buccal mucosa, palate) 1 51 (100.0%) 0 (0.0%) - 51 (100.0%)
0.118
2 50 (92.6%) 4 (7.4%) - 54 (100.0%)
Labial mucosa 1 51 (100.0%) 0 (0.0%) 0 (0.0%) 51 (100.0%)
0.000
2 42 (77.8%) 8 (14.8%) 4 (7.4%) 54 (100.0%)
Gingiva 1 51 (100.0%) 0 (0.0%) 0 (0.0%) 51 (100.0%)
0.040
2 48 (88.9%) 1 (1.9%) 5 (9.3%) 54 (100.0%)
Chi-square test with Yates’s continuity correction, α=5%
1= Solid tumors; 2= Hematologic tumors. Empty spaces= no record of degree of impairment according to the OAG regarding the anatomical 
site/function for the evaluation week
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groups evaluated in this study may have occurred 
due to the condition of the organism according 
the disease type (hematologic or not),28 added to 
immunosuppression after starting the chemotherapy 
treatment,22 which is substantially higher in patients 
with hematologic disease, and in addition to the type 
of the chemotherapy used in the treatment of the 
cancer. Regarding the type of chemotherapy, this 
study found that the antimetabolite agents – the most 
toxic chemotherapeutics to the stomatognathic system 
according to the literature –,6-9 were administered 
mainly to patients with hematologic tumors during 
almost all the evaluation period of this study.
Data from this study enabled the identification 
of the impaired sites with the highest severity, as 
well as the groups of neoplasms with the highest 
Week Chemotherapeutic treatment Group of patients Sig.
Solid tumors Hematologic tumors
1st
1 13 (72.2%) 5 (27.8%)
<0.001
2 9 (22.0%) 33 (78.0%)
3 25 (65.8%) 13 (34.2%)
4 1 (25.0%) 3 (75.0%)
2nd
1 10 (90.9%) 1 (9.1%)
<0.001
2 9 (19.6%) 37 (80.4%)
3 28 (70.0%) 12 (30.0%)
4 1 (25.0%) 3 (75.0%)
Association (1, 3 and 4) 3 (100.0%) 0 (0.0%)
Association (2 and 3) 0 (0.0%) 1 (100.0%)
3rd
1 8 (66.7%) 4 (33.3%)
<0.001
2 10 (100.0%) 0 (0.0%)
3 30 (68.2%) 14 (31.8%)
4 0 (0.0%) 3 (100.0%)
Association (1, 3 and 4) 3 (100.0%) 0 (0.0%)
4th
1 6 (75.0%) 2 (25.0%)
<0.001
2 10 (20.4%) 39 (79.6%)
3 32 (78.0%) 9 (22.0%)
4 0 (0.0%) 3 (100.0%)
Association (1, 3 and 4) 3 (100.0%) 0 (0.0%)
Association (2 and 3) 0 (0.0%) 1 (100.0%)
5th
1 6 (66.7%) 3 (33.3%)
<0.001
2 11 (20.4%) 44 (79.6%)
3 31 (88.6%) 4 (11.4%)
4 0 (0.0%) 3 (100.0%)
Association (1, 3 and 4) 3 (100.0%) 0 (0.0%)
6th
1 9 (100.0%) 0 (0.0%)
<0.001
2 9 (18.8%) 40 (81.2%)
3 30 (75.0%) 10 (25.0%)
4 0 (0.0%) 3 (100.0%)
Association (1, 2 and 3) 0 (0.0%) 1 (100.0%)
Association (1, 3 and 4) 3 (100.0%) 0 (0.0%)
7th
1 7 (77.8%) 2 (22.2%)
<0.001
2 10 (18.9%) 43 (81.1%)
3 31 (88.6%) 4 (11.4%)
4 0 (0.0%) 3 (100.0%)
Association (1, 2 and 3) 0 (0.0%) 1 (100.0%)
Association (1, 3 and 4) 3 (100.0%) 0 (0.0%)
Association (2 and 3) 0 (0.0%) 1 (100.0%)
8th
1 7 (100.0%) 0 (0.0%)
<0.001
2 10 (17.9%) 46 (82.1%)
3 31 (88.6%) 4 (11.4%)
4 0 (0.0%) 3 (100.0%)
Association (1, 2 and 3) 0 (0.0%) 1 (100.0%)
Association (1, 3 and 4) 3 (100.0%) 0 (0.0%)
Table 4- Distribution of patients with solid and hematological tumors according to the chemotherapy protocol used in the treatment of the 
neoplasia, in each of the weeks of the study follow-up
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degrees of impairment, allowing for indications for 
early treatment to prevent the onset of systemic 
complications that result from infectious processes 
on the oral cavity.28
All patients followed in this study were under a 
permanent surveillance protocol regarding the changes 
of normality in the structure and function of the oral 
cavity, as well as being part of a protocol for the 
prevention and treatment of injuries that included the 
topical application of low power laser (calibrated to a 
670 nm wavelength, 40 mW power, and 4 J/cm2 dose 
for 30 s in selected points of oral mucosa) and use of 
mouthwash with a multicomponent solution [nystatin 
(20 ml), dexamethasone (1 ml), diphenhydramine (1 
ml), morphine (1 ml), lidocaine 2% (10 ml), B complex 
(2 ml) and saline solution 0.9% (250 ml)],20 in addition 
to oral hygiene monitoring.
The limitations of this study include the 
methodological difficulties related to the fact that 
pediatric cancer (0-19 years) is rare when compared 
to cancers in the other age groups, which, even using a 
convenience sample with the inclusion of all diagnosed 
patients over a 4-year period, still leads to a reduced 
number sample when compared to oncology studies 
with other age groups. Moreover, the late diagnosis of 
pediatric cancers in Brazil is a reality that compromises 
patient survival and requires cohort monitoring. 
However, this study evaluated patients over a long 
time period when compared to other studies at other 
international centres.24,28 Despite the losses, the study 
sample enabled a satisfactory comparison among 
groups, as performed in this study.
This study showed that during the first month of 
chemotherapy treatment (up to the 5th week), the 
oral alterations changed equally between patients 
with solid and hematologic tumors, and, after the 
1st month (6th, 8th, 9th and 10th weeks), differences 
were observed between the groups of patients, with 
greater involvement by oral mucositis – especially by 
severe oral mucositis –, in patients with hematologic 
tumors. These results show the importance of the 
implementation of oral care in the multiprofessional 
team that provides care to children and adolescents 
in their treatments against a cancer due to the 
identification of oral care needs both in alterations in 
the oral mucosa and oral functions. 
Conclusion
This study concluded that the oral changes during 
the chemotherapeutic treatment occurred especially 
in swallowing function, in the mucous membrane, in 
the labial mucosa and in gingiva, and these alterations 
were mainly presented by patients with hematologic 
tumors.
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